International single-arm protocol to provide expanded access to bortezomib for patients with multiple myeloma who have received at least 2 previous lines of therapy and are refractory to or have relapsed after their last therapy for multiple myeloma

Trial Profile

International single-arm protocol to provide expanded access to bortezomib for patients with multiple myeloma who have received at least 2 previous lines of therapy and are refractory to or have relapsed after their last therapy for multiple myeloma

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Apr 2013

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 23 Oct 2007 The expected completion date for this trial is now 1 Oct 2006.
    • 22 Oct 2007 Status changed from in progress to completed.
    • 04 Apr 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top